Dr. Hyman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1275 York Ave
Box #8, Room C1282
New York, NY 10065Phone+1 212-639-2000- Is this information wrong?
Summary
- I am a medical oncologist who specializes in the treatment of gynecologic cancers. My research interests including developmental therapeutics, gynecologic cancer, rare uterine sarcomas, and BRCA-associated ovarian cancer.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009
Weill Cornell MedicineClass of 2006
Certifications & Licensure
NY State Medical License 2007 - 2025
NJ State Medical License 2019 - 2021
Clinical Trials
- A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1) Start of enrollment: 2010 Jul 01
- Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer Start of enrollment: 2010 Nov 01
- Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
- Join now to see all
Publications & Presentations
PubMed
- Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.Roisin M Connolly, Victoria Wang, David M Hyman, Petros Grivas, Edith P Mitchell, John J Wright, Elad Sharon, Robert J Gray, Lisa M McShane, Larry V Rubinstein, David ...> ;Clinical Cancer Research. 2024 Apr 1
- 7 citationsPhase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.E Borazanci, A M Schram, E Garralda, I Brana, M Vieito Villar, A Spreafico, M Oliva, N J Lakhani, K Hoffman, R M Hallett, D Maetzel, F Hua, J Hilbert, P Giblin, J Anid...> ;ESMO Open. 2022 Aug 1
- 1 citationsNatural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AA...Michele L LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, David M Hyman, Natalie Blauvelt, Philippe L Bedard, Funda Meric-Bernstam, Rinaa S Punglia, Deborah Schrag,...> ;Clinical Cancer Research. 2022 May 13
- Join now to see all
Journal Articles
- Efficacy of MEK Inhibition in Patients with Histiocytic NeoplasmsRobert J Young, Mario Lacouture, Neal Rosen, David M Hyman, Raajit Rampal, Gary A Ulaner, Benjamin H Durham, Lynn A Brody, Nature
- Article Widespread Selection for Oncogenic Mutant Allele Imbalance in CancerSarat Chandarlapaty, Alison M Schram, David M Hyman, David B Solit, ScienceDirect
- Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancerHyman, D.M., Spriggs, D.R., JAMA
- Join now to see all
Abstracts/Posters
- Extended Mutational Profiling By MSK-IMPACTTM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor MalignancyClinically Relevant AbstractDavid M. Hyman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.2019 ASCO Annual Meeting - 6/1/2019
- FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.2019 ASCO Annual Meeting - 6/1/2019
- Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Eli Lilly's Verzenio Snags First-in-Class FDA Approval for Early Breast Cancer. But Limited Label Poses a ChallengeOctober 13th, 2021- FDA Expands Lilly's ERBITUX® (Cetuximab) Label with Combination of BRAFTOVI® (Encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) After Prior TherapySeptember 28th, 2021
- Lilly Presents New Data on Retevmo® (Selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual MeetingApril 11th, 2021
- Join now to see all
Grant Support
- Young Investigator AwardKaleidoscope of Hope Foundation2011–Present
Committees
- Member, SEP Working Group, American Society of Clinical Oncology 2011 - Present
- Member, Investigational New Drug Committee, Memorial Sloan-Kettering Cancer Center 2011 - Present
- Member, Admissions Committee, Weill Cornell Medical College 2010 - Present
- Member, Organization of Resident Representatives, AAMC 2010 - Present
- Member, Fellow Advisory Group, American Society of Clinical Oncology 2009 - Present
Hospital Affiliations
Memorial Sloan Kettering Cancer CenterNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
